Novel glutatione based formulations for targeting the NLRP3 inflammasome in the treatment of cardiovascular diseases

Title : Novel glutatione based formulations for targeting the NLRP3 inflammasome in the treatment of cardiovascular diseases

Abstract:

This presentation will focus on the NLRP3 inflammasome and its involvement in the pathogenesis of cardiovascular diseases, the causes of its activation, and approaches to targeting these causes based on an extrapolation of the mechanism for preventing nitroglycerin tolerance using glutathione. The presentation will describe three novel formulations proposed for preventing the activation of the NLRP3 inflammasome. The three formulations are:1] glutathione + nitroglycerin buffered with arginine;2] formulation 1 + dapagliflozin and 3] formulation 2 minus nitroglycerin. This will be followed by a list of diseases matched to treatment with these formulations. The list of diseases and treatments to be discussed includes advanced heart failure, restenosis, claudication, acute kidney injury, refractory angina and coronary microvascular disease, anthracycline cardiotoxicity, hypertensive disease of pregnancy/preeclampsia, postpartum cardiomyopathy and COVID-19. The presentation will conclude with a plan for FDA CMC studies with these formulations and their suitability for use in newer parental delivery systems.

Audience take Away Notes:

• The role of the NLRP3 inflammasome in the pathogenesis of cardiovascular disease.
• The role of glutathione in nitroglycerin tolerance and its basis for three new formulations for preventing the activation of the NLRP3 inflammasome
• Cardiovascular diseases likely to benefit from the proposed three new formulations.

Biography:

W H Kaesemeyer, MD is an independent research cardiologist whose current focus is preventing the activation of the NLRP3 inflammasome in the treatment of cardiovascular diseases, all as an extrapolation of his work on the cause and prevention of nitroglycerin tolerance. He has practiced for 28 years as a hypertension specialist who is board certified in internal medicine. This followed 4 years of medical school (MD 1978 Wake Forest University, Winston-Salem, NC) and 4 years of residency training that included a year as a chief resident, all of which followed initially working as a pharmaceutical chemist. He has been the principal investigator on 20 clinical trials of hypertension, lipids and heart failure medications. He is an author or co-author of over 35 publications and the inventor of 5 patents involving nitric oxide, nitroglycerin tolerance and statin nitric oxide pleiotropy.